Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca Clinigen Specialty Pharmaceuticals division expands to five products Business Wire BURTON-ON-TRENT, England -- August 20, 2014 Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol^® (amifostine) from AstraZeneca. Ethyol is a cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. In 1995, the US Food and Drug Administration (FDA) granted Ethyol a New Drug Application (NDA) and in 2013, Ethyol revenue was approximately $4.9million. This is the second product Clinigen has acquired from AstraZeneca (the first being the anti-viral Foscavir^® in 2010), and the Group’s third oncology support product adding to Cardioxane^® and Savene^® bringing the Specialty Pharmaceuticals portfolio to five products in total. Under the terms of the agreement, Clinigen will assume full responsibility for the distribution of the product with immediate effect. AstraZeneca, working closely with Clinigen, will continue to manufacture the product whilst the NDA and Investigational New Drug (IND) authorizations are transferred and the technical transfer to a third party manufacturer is completed. The acquisition will be paid for in milestone related stage payments linked to the transfer of manufacturing. The financial terms of the agreement are not disclosed. Fox Rothschild advised on legal matters. Peter George, Chief Executive Officer, Clinigen Group, said: “I am very pleased to be working with the AstraZeneca team again. In acquiring Ethyol, as well as bringing our total number of products to five, we now have a portfolio of three oncology support products, adding to Cardioxane^® and Savene^®. This acquisition is in line with our stated strategy of acquiring niche, hospital-only therapies which have the potential to save and improve the lives of critically ill patients. Ethyol was originally identified through our acquisition database of large pharma product candidates as a very good fit for Clinigen’s business model; whilst it was one of the original 12 targets and took some time to close, it is further evidence that the Clinigen model works.” - Ends - Notes to Editors About Ethyol^® (amifostine) Ethyol is the trihydrate form of amifostine and is supplied as a sterile lyophilized powder requiring reconstitution for intravenous infusion. Each single-use 10 mL vial contains 500 mg of amifostine. Ethyol is used therapeutically to reduce the incidence of neutropenia-related fever and infection induced by DNA-binding chemotherapeutic agents including alkylating agents (e.g. cyclophosphamide) and platinum-containing agents (e.g. cisplatin). It is also used to decrease the cumulative nephrotoxicity associated with platinum-containing agents. Ethyol is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer. About Clinigen Group The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering ‘the right drug, to the right patient at the right time’, has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide, increasing the value of these medicines by developing new formulations and indications, then registering and marketing them in defined global markets. For more information, please visit www.clinigengroup.com. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com Contact: Clinigen Group plc Tel: +44 (0) 1283 495010 Peter George, Group Chief Executive Officer Robin Sibson, Group Chief Financial Officer Shaun Chilton, Group Chief Operating Officer or Numis Securities Limited Tel: +44 (0) 20 7260 1000 Michael Meade/Freddie Barnfield (Nominated Adviser) James Black/Tom Ballard (Corporate Broking) or Peel Hunt LLP - Joint Broker Tel: +44 (0) 20 7418 8900 James Steel / Jock Maxwell Macdonald or Instinctif Partners (media relations) Tel: +44 (0) 20 7457 2020 Melanie Toyne-Sewell/ Jen Lewis Email: email@example.com
Siemens Agrees to Buy Dresser-Rand For $7.6 Billion in All Cash Deal
Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca
Press spacebar to pause and continue. Press esc to stop.